5 mg/ml – Concentrato per soluzione per infusione

DRUG2 trials

Sponsors

AstraZeneca AB, Associazione Italiana Per Lo Studio Del Pancreas

Conditions

Advanced Hepatobiliary Cancerpancreatic ductal adenocarcinoma

Phase 2

A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

RecruitingCTIS2022-502317-29-00

AstraZeneca ABAdvanced Hepatobiliary Cancer

Start: 2023-07-12Target: 60Updated: 2025-12-11

Phase 3

A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)

Not yet recruitingCTIS2024-519031-42-00

Associazione Italiana Per Lo Studio Del Pancreaspancreatic ductal adenocarcinoma

Target: 261Updated: 2024-11-18

Related Papers

Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.

2025-11-20